ARCHIVES

New FDA Commisioner’s Top Priorities: FDAMA Implimitation, Agency’s Science

This article is from The Cancer Letter archive.

Vol. 25 No. 01 | January 8, 1999

Download PDF Visit The Full Archive

Related Articles

20% of Women Do Not Believe Tailored Risk Assessments

August 30, 2013

Study Section Members Seek NIH Use Of Normalization, Sliding Scale

April 16, 1982

Acceptance Of Sentinel Node Biopsy Is Growing, Study Finds

October 31, 2003

AACR Supports 5 Percent Increase in NCI Budget.

April 7, 2006

In Brief: Schepartz To Leave NCI for Academia; Woolley Names To Head Clinical Research At Lombardi

March 9, 1984

Tobacco Company Liggett Gave $3.6 Million To Henschke For CT Screening Research.

March 28, 2008